🏢 官网IRWGSCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:05:00时区推断·⟳ 抓取 04:07:15回填·⚡ 决策 07-17 04:08:11·102.5 天前
GeneDx宣布将于8月3日盘后披露二季度业绩并召开电话会
该公告只是业绩披露时间和电话会安排，不包含二季度经营数据、业绩预告、指引上修或订单等可交易增量。
📄 原文WGS↗ 原文
GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026
Skip to main navigation Release Details GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 202…
不做 GeneDx（WGS.US）
仅为财报发布日期和电话会通知，不含业绩结果、预告、指引或其它方向性增量；当前不做，等待8月3日正式财报数据。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-16 · 扩散 low · price-in 风险 low ↗
关键理由
- 该公告只是业绩披露时间和电话会安排，不包含二季度经营数据、业绩预告、指引上修或订单等可交易增量。
主要风险
- 若8月3日正式业绩披露出现超预期数据，应由届时新信号重新研判。
原文全文
展开原文 · 2,017 字
Skip to main navigation
Release Details
GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026
July 16, 2026
PDF Version
GAITHERSBURG, Md. --(BUSINESS WIRE)--Jul. 16, 2026--
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026 . Management will host a conference call that day to discuss second quarter 2026 financial and operating results at 4:30 p.m. Eastern Time .
Conference Call Details
Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .
About GeneDx
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx ® tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity™ also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn , Facebook , and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260716521245/en/
Investor Relations Contact:
Investors@GeneDx.com
Media Contact:
Press@GeneDx.com
Source: GeneDx
Search Investors
Release Details
GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026
July 16, 2026
PDF Version
GAITHERSBURG, Md. --(BUSINESS WIRE)--Jul. 16, 2026--
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026 . Management will host a conference call that day to discuss second quarter 2026 financial and operating results at 4:30 p.m. Eastern Time .
Conference Call Details
Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .
About GeneDx
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx ® tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity™ also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn , Facebook , and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260716521245/en/
Investor Relations Contact:
Investors@GeneDx.com
Media Contact:
Press@GeneDx.com
Source: GeneDx
Search Investors
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。